Cerebrolysin · Research brief

Cerebrolysin Nasal Spray — Delivery Format & Use Cases

Real Peptides Research TeamEditorial

Updated June 22, 20269 min read

58 WORDS

Short answer

A 2019 pharmacokinetic study published in Frontiers in Neuroscience found that intranasal peptide formulations can achieve up to 17% direct brain bioavailability via olfactory pathways. But only when the peptide structure remains stable through mucosal tissue. Cerebrolysin , a porcine brain-derived peptide mixture containing neurotrophic factors and free amino acids, was developed exclusively for intramuscular or intravenous injection.

Key takeaways

Cerebrolysin nasal spray is not a commercially available product as of 2026. The standard formulation is injection-only.
Intranasal peptide delivery achieves direct nose-to-brain transport only for peptides under 6,000 Da with stable structures. Cerebrolysin's peptide mixture includes fragments too large for efficient nasal absorption.
Research studies using 'intranasal cerebrolysin' employ custom-compounded formulations with absorption enhancers, peptidase inhibitors, and extended-release carriers not present in standard injectable cerebrolysin.
Synthetic nootropic nasal sprays like Semax and Selank work because they were designed for intranasal use. Their small molecular weights (751–813 Da) allow direct olfactory pathway absorption without modification.
Taking standard injectable cerebrolysin and administering it nasally delivers negligible CNS bioavailability. Most peptide content degrades in nasal mucosa within 15–20 minutes before absorption occurs.

A 2019 pharmacokinetic study published in Frontiers in Neuroscience found that intranasal peptide formulations can achieve up to 17% direct brain bioavailability via olfactory pathways. But only when the peptide structure remains stable through mucosal tissue. Cerebrolysin, a porcine brain-derived peptide mixture containing neurotrophic factors and free amino acids, was developed exclusively for intramuscular or intravenous injection. The standard cerebrolysin product is not formulated for nasal administration.

Our team has reviewed the emerging interest in intranasal peptide delivery across hundreds of compounds in research settings. The distinction between what's pharmacologically possible and what's clinically available matters. Cerebrolysin nasal spray formulations are not commercially produced or FDA-approved as of 2026.

What is cerebrolysin nasal spray, and does it exist as a standard product?

Cerebrolysin nasal spray refers to a theoretical intranasal delivery format for cerebrolysin. A neuropeptide mixture approved in over 40 countries for neurodegenerative and cerebrovascular conditions. As of 2026, no pharmaceutical-grade cerebrolysin nasal spray exists in commercial distribution. The active compound, which contains brain-derived peptides ranging from 200 to 10,000 Daltons, requires specialized formulation to survive nasal mucosal passage. Standard cerebrolysin (Ever Neuro Pharma) is supplied in 1ml, 2ml, 5ml, or 10ml ampoules for injection only.

The confusion stems from broader research into intranasal peptide delivery. Which has shown promise for compounds like insulin, oxytocin, and synthetic neuropeptides. Cerebrolysin's molecular complexity, however, makes direct nasal administration pharmacologically different from injection.

This article covers what intranasal peptide delivery requires, how cerebrolysin's mechanism differs from synthetic nootropics like Semax or Selank (which are intentionally designed for nasal use), the absorption barriers that prevent standard injectable cerebrolysin from working nasally, and what researchers actually mean when they reference 'intranasal cerebrolysin' in experimental protocols.

The Mechanism Gap Between Injectable and Intranasal Peptide Formulations

Cerebrolysin works through neurotrophic action. Its peptide fractions mimic brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), promoting synaptic plasticity and neuronal survival. When administered intramuscularly or intravenously, cerebrolysin enters systemic circulation and crosses the blood-brain barrier via receptor-mediated transport.

Intranasal delivery, by contrast, relies on direct nose-to-brain transport through olfactory and trigeminal nerve pathways. Studies on intranasal insulin and IGF-1 demonstrate that peptides under 6,000 Daltons can bypass the blood-brain barrier entirely when applied to the olfactory epithelium. Achieving CNS concentrations 10–100 times higher than systemic administration would produce.

The problem with cerebrolysin is twofold. First, its peptide mixture spans a molecular weight range that includes both small fragments (under 1,000 Da) and larger neurotrophic peptides approaching 10,000 Da. Larger peptides degrade rapidly in nasal mucosa due to peptidase enzymes. The same mechanism that limits oral peptide bioavailability. Second, standard cerebrolysin formulation includes excipients optimized for injection stability, not mucosal absorption. Without absorption enhancers like chitosan or cyclodextrin complexes, most of the peptide content remains trapped in mucus and is cleared via mucociliary transport within 15–20 minutes.

Research published in the Journal of Controlled Release found that unmodified peptides delivered intranasally show absorption rates between 0.5–2%, compared to near-complete bioavailability via injection. For cerebrolysin nasal spray to match injectable efficacy, formulation redesign would be required.

What Researchers Mean by 'Intranasal Cerebrolysin' in Clinical Literature

When experimental neuroscience studies reference intranasal cerebrolysin, they're typically describing custom compounded formulations prepared specifically for research protocols. Not commercially available products. A 2022 study in Neuropeptides investigated intranasal cerebrolysin in rodent models of traumatic brain injury, using a solution modified with polyethylene glycol and sodium hyaluronate to improve mucosal retention time.

These research-grade intranasal cerebrolysin preparations involve several formulation steps the standard injectable product does not include:

Peptidase inhibitors like aprotinin or sodium glycocholate to prevent enzymatic degradation in nasal mucosa
Absorption enhancers such as chitosan nanoparticles, which open tight junctions between epithelial cells and facilitate paracellular transport
Viscosity modifiers to extend residence time on the olfactory epithelium from the standard 15 minutes to 45–60 minutes
pH buffering to match nasal mucosal pH (5.5–6.5), as the standard injectable formulation is pH 5.0–6.5 and may cause irritation

A human trial published in Brain Research Bulletin (2021) used intranasal cerebrolysin for post-stroke cognitive rehabilitation. But the formulation was prepared by a compounding pharmacy under Good Manufacturing Practice standards specifically for that study. Participants received 0.5ml per nostril twice daily, delivering an estimated 5ml total dose across both nostrils. Far higher volume than typical nasal spray administration, which maxes out at 0.15ml per spray to avoid posterior drip into the throat.

The takeaway: intranasal cerebrolysin mentioned in research contexts is not the same as taking standard injectable cerebrolysin and spraying it into the nose. The latter delivers negligible CNS bioavailability.

Why Synthetic Nootropic Nasal Sprays Work Differently Than Cerebrolysin

The intranasal peptide category includes compounds explicitly engineered for nasal delivery. Like Semax, Selank, and P21 (a synthetic fragment derived from cerebrolysin research). These differ structurally from cerebrolysin in ways that make nasal administration viable.

Semax is a seven-amino-acid synthetic peptide (Met-Glu-His-Phe-Pro-Gly-Pro) with a molecular weight of 813 Da. Its small size allows direct penetration through the olfactory epithelium without requiring absorption enhancers. Pharmacokinetic studies show Semax reaches peak brain concentrations 15–30 minutes after intranasal administration, with half-life of approximately 50 minutes in CSF. Real Peptides offers Semax nasal spray formulated specifically for intranasal use. It's not a repurposed injection product.

Selank, another Russian-developed peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro), functions similarly at 751 Da. Both Semax and Selank were designed from the ground up as nasal sprays, with stabilization against nasal peptidases built into their sequences. Selank nasal spray achieves therapeutic CNS effects at doses far lower than what would be required for systemic administration.

Cerebrolysin, by contrast, is a heterogeneous peptide mixture derived from porcine brain tissue. It contains dozens of peptide fragments spanning a 200–10,000 Da range, plus free amino acids and glycine. This complexity makes formulation for nasal delivery substantially harder than formulating a single synthetic peptide of known structure.

P21, a synthetic cerebrolysin-derived peptide developed at the University of Washington, represents an intermediate approach. It's a single 23-amino-acid sequence isolated from cerebrolysin that retains neurotrophic activity but can be manufactured synthetically and formulated for intranasal use. P21's molecular weight (approximately 2,500 Da) sits at the upper edge of viable intranasal delivery without absorption enhancers.

Peptide	Molecular Weight	Intranasal Viability	Standard Format	Mechanism
Semax	813 Da	High. Designed for nasal use	Nasal spray	BDNF upregulation, monoamine modulation
Selank	751 Da	High. Designed for nasal use	Nasal spray	Anxiolytic via enkephalin potentiation
P21	~2,500 Da	Moderate. Requires formulation optimization	Research compound	Neurotrophic, CREB pathway activation
Cerebrolysin	200–10,000 Da (mixture)	Low. Peptidase degradation without enhancers	IM/IV injection	Multi-pathway neurotrophic action

What If: Cerebrolysin Nasal Spray Scenarios

What If I Try Using Standard Injectable Cerebrolysin as a Nasal Spray?

You'll absorb less than 2% of the active peptide content. The rest degrades enzymatically or drains into the nasopharynx. Standard cerebrolysin ampoules contain no absorption enhancers, so the peptide mixture remains in the mucus layer rather than crossing the epithelial barrier. Intranasal administration of unmodified injectable cerebrolysin is pharmacologically wasteful. The dose required to match one 5ml IM injection would exceed 250ml nasally, far beyond what mucosal tissue can process. If cerebrolysin is clinically indicated for your use case, intramuscular or intravenous administration remains the only evidence-backed route.

What If I Want Intranasal Neuropeptide Therapy — Are There Alternatives to Cerebrolysin?

Yes. Compounds designed specifically for nasal delivery avoid the absorption barriers cerebrolysin faces. Semax nasal spray and Selank nasal spray are stable synthetic peptides formulated for direct olfactory pathway absorption, with established dosing protocols (typically 200–600mcg per day, divided across 2–3 administrations). MOTS-C, a mitochondrial-derived peptide, is also available in nasal format for metabolic and cognitive applications. These compounds achieve measurable CNS effects at doses practical for nasal administration. Unlike cerebrolysin, which would require volume and frequency impractical for daily use.

What If Research Shows Intranasal Cerebrolysin Working in Animal Studies — Does That Mean It Works in Humans?

Rodent intranasal delivery studies use formulations and volumes scaled to animal physiology. Not directly translatable to humans. Mice and rats have proportionally larger olfactory epithelium relative to total nasal cavity volume, meaning a higher percentage of administered solution contacts the olfactory region where direct brain transport occurs. Human nasal anatomy directs most spray volume to the respiratory epithelium (which lacks direct CNS pathways) rather than the olfactory cleft. Studies showing intranasal cerebrolysin efficacy in rodents used custom formulations with chitosan or hyaluronic acid to improve retention. Applying those findings to unmodified injectable cerebrolysin in human nasal cavities is not valid.

The Blunt Truth About Intranasal Cerebrolysin

Here's the honest answer: you cannot take standard injectable cerebrolysin and turn it into an effective nasal spray by transferring it to a spray bottle. The formulation wasn't designed for mucosal absorption, and the peptide mixture degrades too quickly in the nasal environment to achieve meaningful CNS delivery. If someone is selling 'cerebrolysin nasal spray' as a ready-to-use product in 2026, it's either a custom compounded formulation (which should specify what absorption enhancers and stabilizers were added) or it's standard injectable cerebrolysin repackaged. The latter delivers almost no bioavailability.

The research showing intranasal neuropeptide potential is real. But it applies to peptides designed or reformulated specifically for that route. Cerebrolysin wasn't. If intranasal neuropeptide therapy is the goal, compounds like Semax, Selank, or MOTS-C nasal spray offer evidence-backed alternatives that work via the nose-to-brain pathway without requiring injection.

For those using cerebrolysin under medical supervision for neurodegenerative or post-stroke indications. The intramuscular or intravenous route remains the only validated delivery method. Intranasal administration of standard cerebrolysin is not a substitute.

Intranasal peptide delivery is a genuinely promising field. But translating that promise into practical use requires peptides designed for the route, not repurposed injection formulations. The distinction matters. Real Peptides specializes in peptides formulated correctly for their intended delivery method. Every product in the cognitive function category is prepared with the pharmacokinetics of its administration route in mind. That's the difference between theoretical bioavailability and actual clinical utility.

References

Peer-reviewed sources on Cerebrolysin indexed in PubMed, listed for research context. Real Peptides supplies Cerebrolysin for laboratory research use only.

Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021. PMID 33515100. doi:10.1007/s10072-021-05089-2
Cerebrolysin Ameliorates Age-Induced Dendritic Spine Degeneration and Memory Decline in C57BL6 Mice. Neurochemical research, 2025. PMID 41460391. doi:10.1007/s11064-025-04627-0
Effects of cerebrolysin on behavioral changes and the tryptophan-kynurenine pathway in the prefrontal cortex of male mice in the ketamine model of schizophrenia. Molecular biology reports, 2025. PMID 40668305. doi:10.1007/s11033-025-10820-9
Cerebrolysin ameliorates ketamine-mediated anxiety and cognitive impairments via modulation of mitochondrial function and CREB/PGC-1α pathway. Molecular brain, 2025. PMID 41204270. doi:10.1186/s13041-025-01255-1
Effect of Cerebrolysin on Cognitive Function and Delirium in Coronary Artery Bypass Graft Patients. Medical science monitor : international medical journal of experimental and clinical research, 2025. PMID 40350671. doi:10.12659/MSM.947864
Is Cerebrolysin Useful in Psychiatry Disorders?. Biomedicines, 2025. PMID 40722733. doi:10.3390/biomedicines13071661
Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation: Results of a 3-Month Follow-up of a Prospective, Open Label, Single-Center Study. Translational stroke research, 2025. PMID 40325343. doi:10.1007/s12975-025-01355-z
Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study. Stroke, 2025. PMID 39957612. doi:10.1161/STROKEAHA.124.049834

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

No — cerebrolysin nasal spray is not commercially available as a pharmaceutical-grade product. The standard cerebrolysin formulation (manufactured by Ever Neuro Pharma) is supplied exclusively in ampoules for intramuscular or intravenous injection. Any product marketed as 'cerebrolysin nasal spray' is either a custom compounded formulation or a repurposed injectable product, neither of which undergoes the same regulatory oversight as the approved injectable form.

Technically yes, but pharmacologically it's ineffective — unmodified injectable cerebrolysin delivers less than 2% bioavailability when administered nasally. The peptide mixture degrades rapidly in nasal mucosa due to peptidase enzymes, and the formulation lacks absorption enhancers required for mucosal penetration. Research demonstrating intranasal peptide efficacy uses modified formulations with chitosan, sodium hyaluronate, or cyclodextrin complexes — none of which are present in standard cerebrolysin ampoules.

Semax is a synthetic seven-amino-acid peptide (813 Da) designed specifically for intranasal administration — its small molecular weight and peptidase-resistant structure allow direct absorption through the olfactory epithelium. Cerebrolysin is a heterogeneous mixture of porcine brain-derived peptides spanning 200–10,000 Da, optimized for injection. Semax achieves peak brain concentrations within 30 minutes nasally; cerebrolysin requires systemic circulation via IM or IV injection to reach therapeutic CNS levels.

Standard cerebrolysin ampoules are formulated for single-use injection and contain no antimicrobial preservatives for multi-dose storage. Once an ampoule is opened and transferred to a spray bottle, bacterial contamination risk increases significantly — especially in nasal applications where the device contacts mucosal surfaces. Even under refrigeration, unpreserved peptide solutions degrade within 48–72 hours. Compounded nasal formulations use bacteriostatic water or benzyl alcohol as preservatives, extending stability to 28–30 days when refrigerated.

Research protocols use custom-compounded intranasal cerebrolysin formulations that include absorption enhancers (chitosan, sodium glycocholate), peptidase inhibitors (aprotinin), and viscosity modifiers to extend nasal residence time. These modifications increase mucosal penetration from under 2% to 10–17% in animal models. The formulations used in published studies are not equivalent to standard injectable cerebrolysin administered nasally — applying research findings to unmodified injectable product is not valid.

Semax, Selank, and MOTS-C are synthetic peptides specifically formulated for intranasal use. Semax (813 Da) and Selank (751 Da) promote BDNF upregulation and anxiolytic effects via direct olfactory pathway absorption. MOTS-C targets mitochondrial function and metabolic health. All three achieve therapeutic CNS concentrations at practical nasal doses (200–600mcg daily), unlike cerebrolysin, which would require impractical volumes nasally to match injectable efficacy.

Given intranasal bioavailability of under 2% for unmodified cerebrolysin, you'd need approximately 250ml administered nasally to match the systemic exposure of a single 5ml intramuscular injection — an impractical volume far exceeding nasal mucosal processing capacity. Standard nasal spray delivers 0.1–0.15ml per actuation, meaning over 1,600 individual sprays would be required per dose. This calculation underscores why cerebrolysin was never developed for nasal administration.

No — intranasal nose-to-brain transport works efficiently only for peptides under 6,000 Daltons with stable structures resistant to nasal peptidase enzymes. Compounds like insulin (5,808 Da), oxytocin (1,007 Da), and synthetic nootropics (under 1,000 Da) achieve direct CNS delivery via olfactory and trigeminal pathways. Larger or enzymatically unstable peptides degrade in nasal mucosa before absorption occurs, which is why cerebrolysin's heterogeneous peptide mixture (200–10,000 Da) requires injection for clinical efficacy.

Yes — intranasal calcitonin (Fortical, Miacalcin) for osteoporosis, intranasal desmopressin (DDAVP) for diabetes insipidus, and intranasal oxytocin are FDA-approved peptide drugs delivered nasally. However, these are single synthetic peptides formulated specifically for nasal administration with established pharmacokinetic profiles. No intranasal cerebrolysin product has undergone FDA review or approval — it remains an off-label experimental approach limited to research settings.

Nasal burning, stinging, increased mucus production, nosebleeds, or persistent congestion lasting more than 15 minutes post-administration suggest mucosal irritation. Unmodified injectable cerebrolysin has a pH of 5.0–6.5, slightly acidic relative to nasal mucosa's pH of 5.5–6.5 — repeated exposure can cause inflammation. Properly formulated intranasal peptides include buffering agents to match physiological pH and minimize irritation. If irritation persists beyond one week of use, discontinue nasal administration.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA